Lixumistat acetate, a chemical derivative of Metformin, is a potent and orally active activator of AMP-activated protein kinase (AMPK), leading to increased AMPK phosphorylation. Lixumistat (acetate) mitigates aging-related cognitive impairment in animal models [1][2]. Lixumistat (acetate) is a potent inhibitor of oxidative phosphorylation (OXPHOS) suitable for solid tumor research [3].
体内研究
Lixumistat (acetate) has no impact on metabolic regulation as assessed by body weight, blood glucose, insulin levels, and lipid metabolite content in mice with diet-induced obesity [1].
Lixumistat (acetate) (50 mg/kg; for 2 months) does not alter body weight, general locomotion, or anxiety levels [2].
Lixumistat (acetate) effectively reduces the aging-induced decline in both novel object recognition memory and spatial working memory [2].
Lixumistat (acetate) markedly enhances AMPK activation in the hippocampus of aged mice [2].
体外研究
Lixumistat (acetate) (0.31-10 μM) induces phosphorylation of AMPKα1 at Thr172 in a dose- and time-dependent manner in NIH3T3 mouse fibroblast cells [1].
Lixumistat (acetate) does not alter the expression of crucial glucose homeostasis enzymes, including glucose-6-phosphatase (G6pase) and phosphoenolpyruvate carboxykinase 1 (Pck1) [1].
搜索
